

1 Predictors of Response and Rational Combinations for the Novel 2 MCL-1 Inhibitor MIK665 in Acute Myeloid Leukemia

3 **Running title:** Stratifying AML Patients for MCL-1 Inhibition

4 **Authors:**

5 Joseph Saad¹, Rhiannon Newman^{1*}, Elmira Khabusheva^{1*}, Sofia Aakko¹, Eric
6 Durand², Mahesh Tambe¹, Heikki Kuusanmäki¹, Alun Parsons¹, Juho J. Miettinen¹,
7 Komal Kumar Javarappa¹, Nemo Ikonen¹, Mika Kontro^{1,3,4}, Kimmo Porkka³, Heiko
8 Maacke², Janghee Woo⁵, Ensar Halilovic⁶, Caroline A. Heckman¹

10 **Affiliations:**

11 ¹ *Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science
12 (HiLIFE), iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki,
13 Helsinki, Finland*

14 ² *Novartis Biomedical Research, Basel, Switzerland*

15 ³ *Department of Hematology, Helsinki University Hospital Comprehensive Cancer
16 Center, Helsinki, Finland*

17 ⁴ *Foundation for the Finnish Cancer Institute, Helsinki, Finland*

18 ⁵ *Winship Cancer Institute of Emory University, Atlanta, GA, USA*

19 ⁶ *Novartis Biomedical Research, Cambridge, MA, USA*

20 * RN and EK contributed equally to this study.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

21 **Correspondence:**

22 Caroline Heckman, PhD

23 Institute for Molecular Medicine Finland (FIMM)

24 University of Helsinki

25 P.O. Box 20 (Tukholmankatu 8)

26 00014 Helsinki, Finland

27 Phone: +358 29 4125769; email: caroline.heckman@helsinki.fi

28

29 **Competing interests:**

30 Sofia Aakko is currently an employee of Faron Pharmaceuticals, and Eric Durand is
31 an employee of Owkin. During their participation in this study, Eric Durand, Janghee
32 Woo, Heiko Maacke, and Ensar Halilovic were employees and shareholders of
33 Novartis. Caroline Heckman received research funding from Novartis related to this
34 work and has received unrelated research funding from BMS/Celgene, Kronos Bio,
35 Oncopeptides, Orion Pharma, WntResearch, and the Innovative Medicines Initiative 2
36 project HARMONY, plus personal fees from Amgen and Autolus. Mika Kontro has
37 received personal fees from Astellas Pharma, AbbVie, Bristol-Myers Squibb, Faron
38 Pharmaceuticals, Novartis and Pfizer outside the submitted work. Kimmo Porkka has
39 received unrelated research funding from Incyte, Novartis and Roche.

40 **Title:** 111/150 characters

41 **Abstract:** 200/200 words

42 **Text:** 4264/4000 words

43 **Figures, tables:** 7/8

44 **References:** 44/60

45 **Abstract**

46 Despite promising anti-leukemic activity of MCL-1 inhibitors in preclinical studies of
47 acute myeloid leukemia (AML), their progress through clinical evaluation has in part
48 been challenged by limited knowledge of patient subgroups suitable for treatment. To
49 stratify patients with AML for MCL-1 inhibitor-based treatment, we evaluated the
50 sensitivity of 42 primary AML samples to MCL-1 inhibitor MIK665 (S64315) and
51 contrasted their molecular profiles. We observed that MIK665 sensitive samples had
52 a more differentiated phenotype, whereas resistant samples displayed higher levels of
53 ABCB1 (MDR1) and the anti-apoptotic protein BCL-XL. Further evaluation revealed
54 that *ABCB1* expression has good predictive performance in identifying MIK665
55 primary resistant samples. To induce sensitivity, we treated MIK665-resistant samples
56 with ABCB1 inhibitor elacridar, BCL-XL inhibitor A1331852, or BCL-2 inhibitor
57 venetoclax in combination with MIK665. While combinations with elacridar and
58 A1331852 were not effective, the combination of MIK665 and venetoclax effectively
59 eliminated AML blasts compared to either of the agents alone. Additionally, the
60 combination restored sensitivity of samples with primary venetoclax resistance.
61 Overall, this study indicates that elevated *ABCB1* expression is a potential predictor
62 of resistance to MIK665 in AML, and that a combination of MIK665 with venetoclax
63 may be effective for overcoming resistance to either MCL-1 or BCL-2 inhibition.

64 Introduction

65 Of the several novel targeted therapies recently approved for the treatment of acute
66 myeloid leukemia (AML), the combinations of azacitidine or low dose cytarabine with
67 the BCL-2 inhibitor venetoclax for newly diagnosed patients unfit for intensive
68 chemotherapy are particularly efficacious for this previously difficult to treat subgroup
69 of patients (1–4). Apoptosis is a tightly regulated molecular process essential for the
70 maintenance of cellular homeostasis, and the deregulation of which is a fundamental
71 hallmark of tumorigenesis (5). The dependency of AML blasts on different anti-
72 apoptotic BCL-2 family members, such as BCL-2, MCL-1, and BCL-XL, to escape
73 apoptosis mark these proteins as ideal targets for therapeutic inhibition (6). Despite
74 significant improvements in overall survival and remission rates, venetoclax-based
75 therapies are challenged by both primary and acquired resistance leading to relapse
76 (7). This raises the need for novel, rational drug combinations capable of attaining
77 deeper and prolonged responses.

78 In AML, elevated MCL-1 expression plays a central role in escape from apoptosis and
79 has been associated with poor patient prognosis (8,9). As such, inhibitors targeting
80 MCL-1 have been evaluated in preclinical studies alone and in combination with BCL-
81 2 inhibitors resulting in encouraging findings (10–13). These results have supported
82 the clinical evaluation of several MCL-1 inhibitors as monotherapies or in combination
83 with BCL-2 inhibitors and hypomethylating agents (14,15). However, the progression
84 of MCL-1 inhibitors towards clinical approval has been hindered by dose-limiting
85 cardiotoxicity and limited knowledge of biomarkers of response (14). Therefore,
86 identification of patient subgroups likely to benefit from MCL-1 inhibition, as well as

87 suitable drug combinations, could improve efficacy and accelerate the development of
88 this drug class.

89 In this study, we evaluated the activity of the MCL-1 inhibitor MIK665 in AML preclinical
90 models. To identify indicators of response, we assessed the *ex vivo* sensitivity of 42
91 AML samples to MIK665 and compared the transcriptional and protein expression
92 profiles of MIK665 sensitive and resistant samples. The drug response groups were
93 clearly distinguished by disease maturation phenotype and specific gene expression
94 patterns. Additionally, we found that *ABCB1* expression is a predictive indicator of
95 MIK665 resistance in AML samples. We also identified the combination of MIK665 and
96 venetoclax as an effective strategy to overcome resistance to either agent in AML cell
97 lines and samples. This study uncovers novel response patterns to MIK665 in AML
98 that could aid the identification of patients that would benefit from MCL-1 inhibitor-
99 based therapy and improve outcome.

100 **Materials and Methods**

101 **Patient samples**

102 Bone marrow (BM) aspirates and matched skin biopsies from patients with AML
103 (n=42), as well as healthy BM control samples (n=2), were collected from the Helsinki
104 University Hospital or the Finnish Hematology Registry and Biobank following written
105 informed consent, according to protocols approved by the local ethics committee
106 (permit numbers 239/13/03/00/2010 and 303/13/03/01/2011), and in compliance with
107 the Declaration of Helsinki. BM mononuclear cells (MNCs) were isolated by Ficoll
108 density gradient centrifugation (GE Healthcare, Buckinghamshire, UK) and suspended
109 in conditioned medium (CM: RPMI 1640, 12.5% HS-5 conditioned medium, 10% fetal
110 bovine serum (FBS), 2 mM L-glutamine, 100 units/ml penicillin and 100 µg/ml
111 streptomycin) (16). All AML samples contained at least 50% malignant MNCs. RNA
112 from the BM MNCs was prepared using the AllPrep DNA/RNA/miRNA Universal kit or
113 miRNeasy mini kit (Qiagen, Hilden, Germany), and then subjected to RNA sequencing
114 as previously described (17). Remaining MNCs from the samples were viably
115 cryopreserved for further experiments. The clinical characteristics of the AML patient
116 samples used are summarized in Table 1.

117 **Multiparametric flow cytometry-based drug testing of patient samples**

118 Viably cryopreserved AML and healthy MNCs were thawed, treated with DNase I, and
119 suspended in CM for *ex vivo* drug testing. All samples were tested with MCL-1
120 inhibitors MIK665 and S63845, and BCL-2 inhibitor venetoclax. The drugs were
121 dissolved in DMSO and pre-plated on 96-well V-bottom plates (Thermo Fisher
122 Scientific, Carlsbad, CA) in 7 increasing concentrations from 0.1 to 1000 nM using an

123 Echo 550 acoustic liquid handler (Labcyte, San Jose, CA, USA). Cells were incubated
124 on the drug plates for 48 h at 37 °C in 5% CO₂. Following initial profiling, selected AML
125 samples (n=9) were taken forward for drug combination testing of MIK665 combined
126 with venetoclax, ABCB1 inhibitor elacridar, or BCL-XL inhibitor A1331852. Each drug
127 was tested in 6 increasing concentrations from 1 and 1000 nM, while the other drug
128 was fixed at 30 nM (Supplementary Figure 1). When the number of cells from a patient
129 sample was insufficient, the combination of MIK665 in increasing concentrations with
130 the other drug fixed at 30 nM was prioritized. Following incubation with the drugs, cells
131 were stained with an antibody panel designed for the identification of myeloid cell
132 populations (Supplementary Table 1). Afterwards, the plates were analyzed using flow
133 cytometry on the iQue Screener PLUS (Intellicyt, Albuquerque, NM, USA) and gating
134 was performed using the ForeCyt software (Intellicyt). All drugs used in single agent
135 and combination screens are summarized in Supplementary Table 2. The gating
136 strategy used is illustrated in Supplementary Figure 2.

137 **Cell line expression and dependency analysis**

138 Publicly available data was downloaded from DepMap portal and analyzed in
139 GraphPad Prism. Gene expression data was available for 45 myeloid leukemia cell
140 lines, and dependency data for 24 myeloid leukemia cell lines. A low Chronos score
141 corresponds to a high gene dependency. Visualization of *BCL2*, *BCL2L1*, and *MCL1*
142 expression and dependency was made for 24 cell lines which had both data sets
143 available.

144 **Cell line culture**

145 HEL, HL-60, MOLM-13, and Kasumi-1 cell lines were purchased from DSMZ
146 (Braunschweig, Germany). MV4-11 cell line was purchased from ATCC (Manassas,

147 VA, USA). HEL, Kasumi-1 and MV4-11 were maintained in RPMI 1640 medium
148 supplemented with 10-20% heat-inactivated FBS, L-glutamine (2 mM), penicillin (100
149 U/mL), and streptomycin (100 mg/mL). All cells were maintained at 37 °C in 5% CO₂.

150 **Generation of venetoclax-resistant (VenR) cell lines**

151 Kasumi-1, MV4-11, MOLM-13, and HL-60 cells were exposed to increasing
152 concentrations of venetoclax (from 12.5 nM – 1000 nM) with the drug concentration
153 being doubled every 2 days, as previously described (18). VenR cell lines were derived
154 from parental cells that continued to proliferate in the presence of 1000 nM of
155 venetoclax.

156 **Knockout of *ABCB1* in HEL cells using CRISPR/Cas9**

157 The gRNA targeting exon ENSE00003398270 of *ABCB1* (5' –
158 AAGTCCAGCCCCATGGATGA– 3') was inserted into the lentiCRISPRv2GFP vector
159 following the protocol as previously described by the Zhang lab (19). Lentiviral
160 particles were generated by transfection of second-generation lentiviral systems into
161 HEK293-FT cells by calcium phosphate transfection (Promega, Madison, WI, USA).
162 The viral suspension was used to transduce HEL cells for 5 days at 37 °C and 5%
163 CO₂. Following this, fluorescence-activated cell sorting of GFP-positive cells into 96-
164 well plates was carried out using the BD Influx cell sorter (Franklin Lakes, NJ, USA).
165 Cells were maintained in 100 µl of complete RPMI media per well and expanded when
166 needed. PCR was used to identify *ABCB1* knockout, which was confirmed by sanger
167 sequencing and western blotting.

168 **CellTiterGlo-based drug testing of cell lines**

169 Cell lines were tested with MIK665 and venetoclax as single agents or in combination
170 in a range of 5 increasing concentrations from 6.25 to 100 nM (Supplementary Figure
171 3). The compounds were added to a 384-well plate using an acoustic liquid handling
172 device Echo 550 (Labcyte). All cell lines were incubated on the drug plates at 37 °C
173 and 5% CO₂ for 48 h. Cell viability was measured by adding 25 µl of CellTiter-Glo
174 reagent (Promega) to each well and luminescence signal read using a PHERAstar
175 plate reader (BMG Labtech, Ortenberg, Germany).

176 **Data Analysis**

177 For drug response assessment, viability readouts from drug treated wells were
178 normalized to negative (DMSO) and positive (benzathonium chloride) controls, and
179 inhibition dose-response curves were generated for each sample and treatment.
180 Consequently, the modified integration of these curves yielded a drug sensitivity score
181 (DSS) as previously described (20). The DSS is directly proportional to the response
182 of a sample to a drug and has a range of 0 to 50. For drug combination synergy
183 readouts, SynergyFinder 2.0 was used for the calculation of ZIP synergy scores (21).

184 Bulk RNA sequencing for AML patient samples was analyzed in-house as previously
185 described, yielding a gene-sample raw count matrix (17,22). Trimmed Mean of M
186 values (TMM) normalization was performed using the edgeR package and counts per
187 million (CPM) values were computed (23). Differential gene expression analysis was
188 performed using a limma-voom pipeline for regression modeling, identifying
189 differentially expressed genes (FDR < 0.1) (24).

190 Confirmatory data analyses were performed using publicly available AML patient
191 sample datasets: TCGA and BEAT AML (25,26).

192 All statistical tests were performed using R software (R version 4.0.0), and
193 nonparametric tests used in cases where the normality of distribution by the Shapiro-
194 Wilk test was not verified. Two group-comparisons were done by the 2-sample t-test
195 or by the Mann Whitney U-test. Correlations between two continuous sets of values
196 were performed using the Pearson or the Spearman method. Multiple testing
197 correction by the Benjamini-Hochberg method was performed when applicable.

198 **Data Availability Statement**

199 RNA sequencing data of AML samples is available in Supplementary Table 3, and drug
200 sensitivity testing results from the single agent screen is available in Supplementary
201 Table 6. For other original data, please contact the corresponding author.

202 For more detailed descriptions of the methodology, see the Supplementary Materials
203 and Methods section. For the full list of western blot antibodies and RT-qPCR primers
204 used, see Supplementary Tables 4 and 5.

205

206 **Results**

207 **Primary AML cells display variable response to MIK665**

208 Dose response of AML samples (n=42) to MCL-1 inhibitor MIK665 was assessed using
209 a multiparametric flow cytometry-based assay. The leukocyte cell viability dose-
210 response curve of each sample was converted into a drug sensitivity score (DSS),
211 directly proportional to the sample's response to MIK665 (Figure 1A). AML leukocyte
212 populations demonstrated a DSS continuum across the samples, ranging from 5.2 to
213 34.9. Based on the DSS distribution, we selected DSS cutoffs of 10 and 20 to
214 represent resistant (n=10) and sensitive (n=15) samples, respectively. The remaining
215 17 samples were defined as intermediate responders (Figure 1B). The effect of
216 MIK665 on the leukocytes of a sensitive and a resistant AML sample is illustrated in
217 Supplementary Figure 4. In parallel, S63845, an MCL-1 inhibitor structurally related to
218 MIK665, was also tested in the samples resulting in a similar response pattern to
219 MIK665 (Supplementary Figure 5) (27). The full list of results obtained from the single
220 agent screening experiments is available in Supplementary Table 6.

221 Viability dose-response curves for leukocyte (CD45+), blast (CD45dim-sidescatter
222 low), monocyte (CD14+) and lymphocyte (CD45high-sidescatter low) subpopulations
223 are illustrated in Figures 1C-F. Of the 42 AML samples, 16 contained a quantifiable
224 monocytic population (representing $\geq 5\%$ of the total leukocytes), 75% (n=12) of which
225 were sensitive to MIK665 (Figure 1E). 23 out of the 42 samples contained a
226 quantifiable lymphocyte population, 96% (n=22) of which were not sensitive to the
227 treatment (Figure 1F). Additionally, MIK665 was tested on BM MNCs from 2 healthy
228 donors. Intermediate DSS values (10 and 12) were observed for the leukocyte
229 populations, with the lymphocyte populations showing similar responses, further

230 indicating that MIK665 has a limited effect on healthy hematopoietic cells (Figure 1G-
231 H). Together, these data indicated that MIK665 was particularly effective in AML cells
232 differentiated towards the monocytic lineage, while its effect on lymphocytes was
233 limited.

234 **High expression of ABCB1 or BCL-XL is associated with resistance to MIK665**

235 To identify molecular indicators distinguishing MIK665-sensitive (n=15) and resistant
236 (n=10) samples, we performed differential gene expression analysis. The genes
237 analyzed were restricted to protein-coding genes having sufficiently high expression
238 level (Supplementary Materials and Methods). 112 genes were differentially expressed
239 (FDR < 0.1), 74 of which were upregulated and 38 were downregulated in MIK665-
240 resistant compared to sensitive samples (Figure 2A, Supplementary Table 7).

241 *ABCB1* was among the most enriched genes in the resistant samples, with a log₂ fold
242 change of -3.54 (Figure 2A). Encoding the multi-drug resistance protein MDR1, also
243 known as P-gp, *ABCB1* is associated with multi-class drug resistance in a range of
244 cancers (28). *ABCB1* expression level was significantly upregulated in MIK665-
245 resistant samples compared to both intermediate and sensitive samples
246 (Supplementary Figure 6A). Across the samples, *ABCB1* expression was significantly
247 inversely correlated to MIK665 DSS, indicating that *ABCB1* expression can be used
248 as a marker of MIK665 resistance (Figure 2B). The difference in expression of *ABCB1*
249 between the highest and lowest expressing samples was validated by RT-qPCR
250 (Supplementary Figure 7, Supplementary Methods). To confirm *ABCB1* expression at
251 the protein level, we performed western blotting on a set of 12 samples (8 with low
252 *ABCB1* and 4 with high *ABCB1* RNA expression). In concordance with the
253 transcriptomic data, elevated levels of *ABCB1* were detected in MIK665-resistant, but

254 not in sensitive samples (Figure 2D, Supplementary Figure 8, Supplementary
255 Methods).

256 Of the BCL-2 family members, *BCL2L1*, encoding the anti-apoptotic protein BCL-XL,
257 had the highest expression in the resistant samples (Figure 2A, Supplementary Figure
258 6B). As with *ABCB1*, we detected a significant inverse correlation between *BCL2L1*
259 expression and MIK665 DSS (Figure 2C). Interestingly, *BCL2L1* levels positively
260 correlated with *ABCB1* levels in our sample cohort, a finding we confirmed in two
261 publicly available datasets: BEAT and TCGA (Supplementary Figure 6C-E). Western
262 blot analysis showed higher BCL-XL protein expression in MIK665-resistant compared
263 to sensitive samples in our cohort. BCL-2 and MCL-1 levels varied across the sensitive
264 and resistant samples, indicating that neither was linked to primary MIK665 resistance
265 (Figure 2D, Supplementary Figure 8).

266 Together, these results indicate that high *ABCB1* and high BCL-XL levels are useful
267 indicators of MIK665 resistance and could constitute potential mechanisms of
268 resistance to the drug in AML.

269 **Differentiation markers *LILRA2* and *IL17RA* are associated with MIK665** 270 **sensitivity**

271 Differential gene expression analysis showed *LILRA2* and *IL17RA*, encoding
272 leukocyte immunoglobulin-like and low affinity interleukin 17A receptors, respectively,
273 to be among the top upregulated genes in MIK665-sensitive samples, with significantly
274 higher expression levels compared to the intermediate and resistant samples (Figure
275 2A). In line with this finding, expression values of both genes were significantly
276 correlated with MIK665 DSS values (Supplementary Figure 9A-D). Similar to *MCL1*,
277 *LILRA2* and *IL17RA* are known to be associated with hematopoietic cell differentiation,

278 notably monocytic and polymorphonuclear lineages (Supplementary Figure 10). To
279 study the implications of this expression pattern on MIK665 sensitivity, we compared
280 MIK665 response levels in our cohort across differentiation subtypes based on the
281 French-American-British (FAB) classification. AML samples with a more differentiated
282 cellular phenotype (FAB M4 or M5) were generally more sensitive to MIK665
283 compared to immature samples (FAB M0/M1 or M2), even though a small subset of
284 less differentiated samples was also responsive (Supplementary Figure 9E). These
285 findings suggest that more differentiated AML phenotypes, characterized by high
286 *LILRA2* and *IL17RA* expression, are more likely to be sensitive to MCL-1 inhibition by
287 MIK665, in line with our observation that MIK665 is more effective in monocytic
288 populations.

289 **AML cell lines with high *ABCB1* expression demonstrate distinct dependency** 290 **patterns on *BCL-2* family members**

291 To further investigate potential relationships between *ABCB1* and *BCL2* family anti-
292 apoptotic genes, we analyzed gene expression (n=45) and dependency data (n=24)
293 of AML cell lines (Figure 3A and 3B; Supplementary Figure 11). Cell lines were
294 categorized as having a high ($\log_2\text{CPM} > 2$) or low ($\log_2\text{CPM} < 2$) *ABCB1* expression,
295 and the two groups were contrasted for their expression of and dependence on *BCL2*,
296 *MCL1*, and *BCL2L1*. AML cell lines with high *ABCB1* expression had significantly
297 reduced *BCL2* and significantly increased *BCL2L1* expression compared to the cell
298 lines with low *ABCB1* level, while no difference in the *MCL1* expression was detected
299 between the two groups (Figure 3C). Concordantly, AML cell lines with high *ABCB1*
300 expression demonstrated significantly higher dependency on *BCL2L1*, as well as
301 significantly reduced *BCL2* and *MCL1* dependency (Figure 3D). Together, these

302 findings suggest that AML cell lines exhibiting elevated *ABCB1* expression are more
303 dependent on BCL-XL than on MCL-1 or BCL-2 for survival.

304 ***ABCB1* expression is a strong predictive biomarker of MIK665 resistance**

305 To evaluate the predictive effect of *ABCB1* expression on MIK665 response in AML
306 samples, we plotted the distribution of *ABCB1* expression values across the response
307 subgroups in our cohort. The density curves of expression per subgroup showed
308 distinct peaks, with the biggest separation difference between the resistant subgroup
309 compared to the sensitive and intermediate subgroups (Figure 4A, Supplementary
310 Figure 6A). We then performed a receiver operating characteristics (ROC) curve
311 analysis to assess the ability of *ABCB1* expression to distinguish MIK665-resistant
312 from sensitive and intermediate samples. The cutoff with the optimal classifying
313 performance for *ABCB1* expression was 5.22 (log2CPM) as identified using the
314 Youden index. This resulted in an area under the ROC curve of 0.856, with a sensitivity
315 of 80%, a specificity of 90.6%, and a positive predictive value of 72.7% (Figure 4B-C).

316 ***ABCB1* inhibition does not overcome MIK665 resistance**

317 As *ABCB1* is a known driver of multidrug resistance across several cancer types, we
318 sought to evaluate its role as a potential target in MIK665 resistant AML. We selected
319 three *ABCB1* high (MIK665 DSS < 15) and three *ABCB1* low (MIK DSS > 35) samples
320 and tested these with the *ABCB1* inhibitor elacridar in combination with MIK665. The
321 combination of elacridar and MIK665 did not result in significantly higher responses in
322 the *ABCB1* high samples, compared to either agent alone (Figure 4D). To further
323 explore if *ABCB1* inhibition can restore sensitivity to MIK665, we tested the MIK665
324 and elacridar combination in the HEL AML cell line. The HEL cell line was selected due
325 to its high *ABCB1* expression level and was therefore expected to be resistant to MCL-

326 1 inhibition by MIK665 (Figure 3A). However, HEL cells did not respond to either drug
327 individually or in combination, indicating that chemical inhibition of ABCB1 cannot
328 restore sensitivity to MCL-1 inhibition by MIK665. To mechanistically investigate the
329 role of ABCB1 in MIK665 resistance, we generated a HEL ABCB1 knockout cell line
330 using CRISPR-Cas9 (Figure 4E). Upon testing of MIK665 in the HEL ABCB1 knockout
331 cells, drug sensitivity was not increased when compared with HEL parental and HEL
332 non-target control (Figure 4F). Overall, we conclude that ABCB1 targeting cannot
333 reverse MIK665 resistance, however, elevated *ABCB1* expression serves as a
334 predictive biomarker of MIK665 resistance in AML.

335 **MIK665 combined with venetoclax is an effective combination in AML samples**
336 **with primary resistance to either of the single agents**

337 To evaluate whether co-targeting other anti-apoptotic proteins is effective in MIK665-
338 resistant samples, we tested combinations of MIK665 with BCL-XL inhibitor A-
339 1331852 or BCL-2 inhibitor venetoclax. The combination of MIK665 and A-1331852
340 did not result in increased sensitivity of the MIK665-resistant samples compared to
341 treatment with MIK665 alone, indicating that co-targeting of BCL-XL and MCL-1 does
342 not restore MIK665 sensitivity (Supplementary Figure 12). However, all three MIK665-
343 resistant samples had significantly higher DSS values to the MIK665 and venetoclax
344 combination compared to MIK665 alone, which suggest that targeting both MCL-1 and
345 BCL-2 is an effective strategy to overcome resistance to MIK665 (Figure 5A).
346 Interestingly, we noticed that one of the MIK665-resistant samples that responded well
347 to the combination also had *ex vivo* primary resistance to venetoclax. To further assess
348 the potential use of this combination in the context of primary venetoclax resistance,
349 we tested three additional samples with primary venetoclax resistance

350 (Supplementary Figure 5, Supplementary Table 6). The combination showed
351 significantly higher DSS values in all three samples compared to venetoclax alone
352 (Figure 5A). The venetoclax dose-response curves with MIK665 fixed at 30 nM further
353 illustrated the benefit of the addition of MIK665 to venetoclax in these samples (Figure
354 5B). Together, these results demonstrate that a combination of MIK665 and venetoclax
355 is an efficacious strategy to overcome primary resistance to either of the two agents.

356 **MIK665 combined with venetoclax restores sensitivity in AML cell lines with** 357 **acquired venetoclax resistance**

358 As acquired resistance to venetoclax is commonly observed following venetoclax-
359 based treatment, we tested the MIK665 and venetoclax combination in AML cell line
360 models with acquired venetoclax resistance. We generated VenR cell lines MV4-
361 11_VenR, Kasumi-1_VenR, MOLM-13_VenR and HL-60_VenR by exposing parental
362 cell lines to increasing concentrations of venetoclax. In all VenR cell lines, MIK665 in
363 combination with venetoclax restored sensitivity. The combination showed high
364 synergy in all cell lines, with a greater effect in MV4-11_VenR and MOLM-13_VenR
365 (Figure 6A). Comparison of BCL-2 family protein levels of parental and VenR cell lines
366 showed a trend towards a decrease in BCL-2 expression and an increase in BCL-XL
367 expression upon acquired venetoclax resistance (Figure 6B). These findings show that
368 MIK665 restores sensitivity to venetoclax in AML with acquired venetoclax resistance,
369 indicating the potential clinical relevance of this combination upon patient relapse to
370 venetoclax-based treatment regimens.

371 Discussion

372 Our assessment of MCL-1 inhibitor MIK665 activity in primary AML patient samples
373 resulted in varied responses, reflecting the heterogeneous response observed in
374 clinical trials (14,15). *ABCB1* was among the most significantly upregulated genes in
375 the MIK665-resistant samples, and logistic regression and ROC curve analyses
376 revealed a strong performance of *ABCB1* expression in identifying MIK665-resistant
377 samples. Nonetheless, direct *ABCB1* inhibition did not reverse MIK665 resistance.
378 Instead, co-inhibition of MCL1 and BCL2 by the addition of venetoclax proved to be
379 an effective strategy in the MIK665-resistant population.

380 *ABCB1*, commonly referred to as multidrug resistance protein 1 (MDR1) or P-
381 glycoprotein (P-gp), can confer resistance to several cancer therapeutics (29). Our
382 previous research has demonstrated that *ABCB1*-mediated drug efflux represents a
383 resistance mechanism to MCL-1 inhibitors in multiple myeloma (30). In AML, the
384 chemotherapeutic daunorubicin is a known *ABCB1* substrate, and high *ABCB1*
385 expression is enriched in adverse European LeukemiaNet (ELN) risk subgroups with
386 poor outcome in patients treated with standard chemotherapy (31–33). To determine
387 whether *ABCB1* inhibition can overcome MIK665 resistance in AML, we evaluated the
388 efficacy of a combination of MIK665 and third generation *ABCB1*-specific inhibitor
389 elacridar in samples with high *ABCB1* expression and low response to MIK665.
390 However, the combination was not more effective compared to MIK665 alone. This is
391 in line with previous studies showing that *ABCB1* expression associates with
392 resistance to intensive chemotherapy in AML patients, but that its co-inhibition does
393 not improve prognosis (33). Furthermore, knockout of *ABCB1* using CRISPR-Cas9 in
394 AML cells having a high basal level of *ABCB1* expression and resistance to MIK665,

395 did not lead to an increased sensitivity. Together, these data indicate that while *ABCB1*
396 does not represent a suitable target to overcome MIK665 resistance, high *ABCB1*
397 expression can be used as a biomarker of *ex vivo* MIK665 resistance in AML.

398 We found *BCL2L1*, a gene encoding the anti-apoptotic protein BCL-XL, to be
399 significantly correlated with *ABCB1* expression in three AML patient cohorts. Previous
400 research has reported that high levels of BCL-XL correlate with resistance to MCL-1
401 inhibition (13,27,34), a finding also observed in this study's MIK665-resistant patient
402 samples. AML cell line analysis further demonstrated that high *ABCB1* expression had
403 significantly higher expression of and dependence on *BCL2L1*. Kuusanmäki et al.
404 found that high BCL-XL expression was correlated with sensitivity to BCL-XL inhibitors
405 in erythroleukemia (FAB M6/M7) (34). However, in our study MIK665-resistant
406 samples did not respond to the BCL-XL inhibitor A1331852 alone or in combination
407 with MIK665. This is likely due to our cohort lacking samples with M6/M7 phenotypes.
408 Further analysis indicated that *ABCB1* and *BCL2L1* were significantly enriched in FAB
409 types M0/M1 and M2 compared to M4 and M5 (Supplementary Figure 13,
410 Supplementary Table 8). Supporting this, samples in our cohort with higher expression
411 levels of *LILRA2* and *IL17RA*, markers of phenotypically mature monocytic-like AML
412 subtypes (notably M4 and M5), were more sensitive to MCL-1 inhibition by MIK665
413 (35). These results align with earlier studies demonstrating that AML FAB subtypes M4
414 and M5 have higher expression of and dependence on MCL-1 and are thus sensitive
415 to MCL-1 inhibition (36,37).

416 *In vitro* studies have indicated that MCL-1 inhibitors synergize with BCL-2 inhibitors,
417 namely venetoclax, leading to the evaluation of this combination for AML patients in
418 several clinical trials. (11,13,15). Aligning with these observations, we found that the

419 combination of MIK665 and venetoclax is effective in samples with MIK665 primary
420 resistance. Interestingly, this combination was also effective in AML samples with
421 primary venetoclax resistance, a finding with important clinical relevance, since up to
422 30% of AML patients treated with venetoclax-based regimens are found to be primary
423 refractory to the treatment (2,38–41). Previous clinical trials have reported cases of
424 disease progression and acquired resistance to venetoclax-based therapies following
425 initial remissions in over 50% of patients until time last of follow-up, leaving them with
426 limited treatment options and a dismal prognosis (40,42). Using AML cell lines with
427 acquired venetoclax resistance as a model for clinical venetoclax relapse, we
428 observed that the MIK665 and venetoclax combination was also highly effective in this
429 context. This is in line with previous findings showing that MCL1-upregulation
430 contributes to acquired venetoclax resistance, and that the addition of an MCL-1
431 inhibitor has the potential to restore sensitivity (43,44). Overall, the combination of
432 MIK665 and venetoclax was effective in AML patient samples with primary resistance
433 to either of the single agents, as well as AML cell lines with acquired venetoclax
434 resistance, a finding warranting further clinical evaluation. The elevated sensitivity of
435 such AML patient subgroups to the combination of MIK665 and venetoclax suggests
436 that lower treatment doses could be administered, thereby improving toxicity profiles,
437 which have so far represented a major obstacle for MCL-1 inhibitor development.

438 In summary, the associations between diverse molecular features of AML samples and
439 their sensitivity to MIK665 described in this study provide valuable insights from a
440 precision medicine and clinical trial design viewpoint. Our study identifies a sizable
441 target AML patient population with differentiated disease that is susceptible to MCL-1
442 inhibition by MIK665. Moreover, we show that elevated *ABCB1* expression represents
443 a predictive biomarker of resistance to MIK665, which can be overcome by the addition

444 of venetoclax. Our findings support the evaluation of the combination of MIK665 with
445 venetoclax in resistant patient populations to restore and prolong clinical responses.

446 **Acknowledgements**

447 The authors of this work would like to thank the Finnish Hematology Registry and
448 Clinical Biobank for providing the patient samples and data, the contributing clinicians
449 and nurses, and especially the donors. The authors also acknowledge the FIMM High
450 Throughput Biomedicine Unit for the drug plate preparation, as well as the FIMM
451 Technology Center sequencing and bioinformatics units for preparing and curating the
452 samples' molecular profiles. The units are hosted by the University of Helsinki and are
453 supported by HiLIFE and Biocenter Finland. This work is expected to contribute to the
454 fulfillment of the PhD requirements of J.S. and R.N., both doctoral candidates at the
455 University of Helsinki. The authors would like to extend further thanks to Minna Suvela
456 and Siv Knaappila for processing the samples used in the study, and to Lisa Eick for
457 providing input into the biomarker analysis. The authors also appreciate the valuable
458 input and revisions received from colleagues at FIMM, Novartis, the Helsinki University
459 Hospital and Comprehensive Cancer Center and Servier Laboratories. This work was
460 supported by funding received by C.A.H. from Novartis, the Research Council of
461 Finland (grant no. 334781, 352265, 357686, and 320185), the Sigrid Jusélius
462 Foundation, and the Cancer Foundation Finland.

463 **Author contributions**

464 J.S., R.N., E.K., S.A., H.K., M.T., A.P., J.M. and K.K. designed and performed the
465 experimental work. J.S., R.N., E.K., N.I., and E.D. carried out the result analysis and
466 interpretation. J.S. and R.N. drafted the manuscript, and all authors contributed to its
467 revision. C.A.H. and E.H. conceived and supervised the study. C.A.H. provided
468 infrastructure to carry out the work.

469 **References**

- 470 1. Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax plus
471 LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3
472 randomized placebo-controlled trial. *Blood* [Internet]. 2020 Jun 11 [cited 2024 Apr
473 11];135(24):2137–45. Available from: <https://pubmed.ncbi.nlm.nih.gov/32219442/>
- 474 2. DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine
475 and Venetoclax in Previously Untreated Acute Myeloid Leukemia. *N Engl J Med*
476 [Internet]. 2020 Aug 13 [cited 2024 Apr 11];383(7):617–29. Available from:
477 <https://pubmed.ncbi.nlm.nih.gov/32786187/>
- 478 3. Bhansali RS, Pratz KW, Lai C. Recent advances in targeted therapies in acute myeloid
479 leukemia. *Journal of Hematology & Oncology* 2023 16:1 [Internet]. 2023 Mar 25 [cited
480 2024 Nov 1];16(1):1–27. Available from:
481 <https://jhoonline.biomedcentral.com/articles/10.1186/s13045-023-01424-6>
- 482 4. Totiger TM, Ghoshal A, Zabroski J, Sondhi A, Bucha S, Jahn J, et al. Targeted Therapy
483 Development in Acute Myeloid Leukemia. *Biomedicines* [Internet]. 2023 Feb 1 [cited
484 2024 Nov 1];11(2):641. Available from:
485 <https://pmc.ncbi.nlm.nih.gov/articles/PMC9953553/>
- 486 5. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. *Cell* [Internet].
487 2011 Mar 4 [cited 2024 Nov 1];144(5):646–74. Available from:
488 <http://www.cell.com/article/S0092867411001279/fulltext>
- 489 6. Krawiec K, Strzałka P, Czemerska M, Wiśnik A, Zawlik I, Wierzbowska A, et al. Targeting
490 Apoptosis in AML: Where Do We Stand? *Cancers (Basel)* [Internet]. 2022 Oct 1 [cited
491 2024 Nov 1];14(20). Available from: <https://pubmed.ncbi.nlm.nih.gov/36291779/>
- 492 7. Garciaz S, Hospital MA, Collette Y, Vey N. Venetoclax Resistance in Acute Myeloid
493 Leukemia. *Cancers* 2024, Vol 16, Page 1091 [Internet]. 2024 Mar 8 [cited 2024 Nov
494 1];16(6):1091. Available from: <https://www.mdpi.com/2072-6694/16/6/1091/htm>
- 495 8. Glaser SP, Lee EF, Trounson E, Bouillet P, Wei A, Fairlie WD, et al. Anti-apoptotic Mcl-1
496 is essential for the development and sustained growth of acute myeloid leukemia.
497 *Genes Dev* [Internet]. 2012 Jan 15 [cited 2024 Nov 1];26(2):120. Available from:
498 <https://pmc.ncbi.nlm.nih.gov/articles/PMC3273836/>
- 499 9. Li XX, Zhou JD, Wen XM, Zhang TJ, Wu DH, Deng ZQ, et al. Increased MCL-1 expression
500 predicts poor prognosis and disease recurrence in acute myeloid leukemia. *Onco*
501 *Targets Ther* [Internet]. 2019 [cited 2024 Nov 1];12:3295. Available from:
502 <https://pmc.ncbi.nlm.nih.gov/articles/PMC6503339/>
- 503 10. Szlavik Z, Csekei M, Paczal A, Szabo ZB, Sipos S, Radics G, et al. Discovery of S64315, a
504 Potent and Selective Mcl-1 Inhibitor. *J Med Chem* [Internet]. 2020 Nov 25 [cited 2024
505 Nov 1];63(22):13762–95. Available from: <https://pubmed.ncbi.nlm.nih.gov/33146521/>
- 506 11. Ramsey HE, Fischer MA, Lee T, Gorska AE, Arrate MP, Fuller L, et al. A Novel MCL1
507 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous

- 508 Leukemia. *Cancer Discov* [Internet]. 2018 Dec 1 [cited 2024 Nov 1];8(12):1566–81.
509 Available from: <https://pubmed.ncbi.nlm.nih.gov/30185627/>
- 510 12. Tron AE, Belmonte MA, Adam A, Aquila BM, Boise LH, Chiarparin E, et al. Discovery of
511 Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and
512 acute myeloid leukemia. *Nat Commun* [Internet]. 2018 Dec 1 [cited 2024 Nov 1];9(1).
513 Available from: <https://pubmed.ncbi.nlm.nih.gov/30559424/>
- 514 13. Caenepeel S, Brown SP, Belmontes B, Moody G, Keegan KS, Chui D, et al. AMG 176, a
515 Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in
516 Combination with Established Therapies. *Cancer Discov* [Internet]. 2018 Dec 1 [cited
517 2024 Nov 1];8(12):1582–97. Available from:
518 <https://pubmed.ncbi.nlm.nih.gov/30254093/>
- 519 14. Tantawy SI, Timofeeva N, Sarkar A, Gandhi V. Targeting MCL-1 protein to treat cancer:
520 opportunities and challenges. *Front Oncol* [Internet]. 2023 [cited 2024 Jul 4];13.
521 Available from: [/pmc/articles/PMC10436212/](https://pmc/articles/PMC10436212/)
- 522 15. Wei AH, Roberts AW, Spencer A, Rosenberg AS, Siegel D, Walter RB, et al. Targeting
523 MCL-1 in hematologic malignancies: Rationale and progress. *Blood Rev* [Internet].
524 2020 Nov 1 [cited 2024 Apr 11];44. Available from:
525 <https://pubmed.ncbi.nlm.nih.gov/32204955/>
- 526 16. Karjalainen R, Pemovska T, Popa M, Liu M, Javarappa KK, Majumder MM, et al. JAK1/2
527 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced
528 protection of AML. *Blood* [Internet]. 2017 Aug 10 [cited 2024 Apr 11];130(6):789–802.
529 Available from: <https://pubmed.ncbi.nlm.nih.gov/28619982/>
- 530 17. Kumar A, Kankainen M, Parsons A, Kallioniemi O, Mattila P, Heckman CA. The impact of
531 RNA sequence library construction protocols on transcriptomic profiling of leukemia.
532 *BMC Genomics* [Internet]. 2017 Aug 17 [cited 2024 Apr 11];18(1):1–13. Available from:
533 <https://bmcgenomics.biomedcentral.com/articles/10.1186/s12864-017-4039-1>
- 534 18. Tambe M, Unterberger S, Kriegbaum MC, Vanttinen I, Olgac EJ, Vähä-Koskela M, et al.
535 Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid
536 leukemia cells and induces vulnerability to PARP inhibition and azacitidine. *Cell Death
537 & Disease* 2024 15:10 [Internet]. 2024 Oct 16 [cited 2024 Nov 1];15(10):1–9. Available
538 from: <https://www.nature.com/articles/s41419-024-07140-4>
- 539 19. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using
540 the CRISPR-Cas9 system. *Nature Protocols* 2013 8:11 [Internet]. 2013 Oct 24 [cited
541 2024 Jul 19];8(11):2281–308. Available from:
542 <https://www.nature.com/articles/nprot.2013.143>
- 543 20. Yadav B, Pemovska T, Szwajda A, Kuleskiy E, Kontro M, Karjalainen R, et al.
544 Quantitative scoring of differential drug sensitivity for individually optimized
545 anticancer therapies. *Scientific Reports* 2014 4:1 [Internet]. 2014 Jun 5 [cited 2024 Apr
546 11];4(1):1–10. Available from: <https://www.nature.com/articles/srep05193>
- 547 21. Ianevski A, Giri AK, Aittokallio T. SynergyFinder 2.0: visual analytics of multi-drug
548 combination synergies. *Nucleic Acids Res* [Internet]. 2020 Jul 2 [cited 2024 Apr
549 11];48(W1):W488–93. Available from: <https://dx.doi.org/10.1093/nar/gkaa216>

- 550 22. Kivioja JL, Thanasopoulou A, Kumar A, Kontro M, Yadav B, Majumder MM, et al.
551 Dasatinib and navitoclax act synergistically to target NUP98-NSD1 +/FLT3-ITD+ acute
552 myeloid leukemia. *Leukemia*. 2019 Jun;33(6):1360–72.
- 553 23. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential
554 expression analysis of digital gene expression data. *Bioinformatics* [Internet]. 2010 Nov
555 11 [cited 2024 Nov 1];26(1):139–40. Available from:
556 <https://pubmed.ncbi.nlm.nih.gov/19910308/>
- 557 24. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential
558 expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res*
559 [Internet]. 2015 Jan 6 [cited 2024 Apr 11];43(7):e47. Available from:
560 <https://pubmed.ncbi.nlm.nih.gov/25605792/>
- 561 25. The Cancer Genome Atlas Research Network. Genomic and Epigenomic Landscapes of
562 Adult De Novo Acute Myeloid Leukemia. *New England Journal of Medicine* [Internet].
563 2013 May 30 [cited 2024 Nov 1];368(22):2059–74. Available from:
564 <https://www.nejm.org/doi/full/10.1056/NEJMoa1301689>
- 565 26. Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, et al. Functional
566 genomic landscape of acute myeloid leukaemia. *Nature* 2018 562:7728 [Internet].
567 2018 Oct 17 [cited 2024 Jul 20];562(7728):526–31. Available from:
568 <https://www.nature.com/articles/s41586-018-0623-z>
- 569 27. Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G, et al.
570 The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. *Nature*
571 2016 538:7626 [Internet]. 2016 Oct 19 [cited 2024 Apr 11];538(7626):477–82.
572 Available from: <https://www.nature.com/articles/nature19830>
- 573 28. Skinner KT, Palkar AM, Hong AL. Genetics of ABCB1 in Cancer. *Cancers (Basel)*
574 [Internet]. 2023 Sep 1 [cited 2024 Nov 1];15(17):4236. Available from:
575 <https://pmc.ncbi.nlm.nih.gov/articles/PMC10487083/>
- 576 29. Khan SU, Fatima K, Aisha S, Malik F. Unveiling the mechanisms and challenges of
577 cancer drug resistance. *Cell Communication and Signaling* 2024 22:1 [Internet]. 2024
578 Feb 12 [cited 2024 Jul 16];22(1):1–26. Available from:
579 <https://biosignaling.biomedcentral.com/articles/10.1186/s12964-023-01302-1>
- 580 30. Bolomsky A, Miettinen JJ, Malyutina A, Besse A, Huber J, Fellingner S, et al.
581 Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1
582 inhibitor resistance in multiple myeloma. *Blood Adv* [Internet]. 2021 Oct 26 [cited
583 2024 Nov 1];5(20):4125. Available from:
584 <https://pmc.ncbi.nlm.nih.gov/articles/PMC8945627/>
- 585 31. Niu J, Peng D, Liu L. Drug Resistance Mechanisms of Acute Myeloid Leukemia Stem
586 Cells. *Front Oncol* [Internet]. 2022 Jul 5 [cited 2024 Nov 1];12:896426. Available from:
587 <https://pmc.ncbi.nlm.nih.gov/articles/PMC9294245/>
- 588 32. Guerci A, Merlin JL, Missoum N, Feldmann L, Marchai S, Witz F, et al. Predictive Value
589 for Treatment Outcome in Acute Myeloid Leukemia of Cellular Daunorubicin
590 Accumulation and P-Glycoprotein Expression Simultaneously Determined by Flow
591 Cytometry. *Blood*. 1995 Apr 15;85(8):2147–53.

- 592 33. Boyer T, Gonzales F, Barthélémy A, Marceau-Renaut A, Peyrouze P, Guihard S, et al.
593 Clinical Significance of ABCB1 in Acute Myeloid Leukemia: A Comprehensive Study.
594 *Cancers (Basel)* [Internet]. 2019 Sep 1 [cited 2024 Nov 1];11(9). Available from:
595 <https://pubmed.ncbi.nlm.nih.gov/31500210/>
- 596 34. Kuusanmäki H, Dufva O, Vähä-Koskela M, Leppä AM, Huuhtanen J, Vääntinen I, et al.
597 Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax
598 resistance in acute myeloid leukemia. *Blood* [Internet]. 2023 Mar 30 [cited 2024 Nov
599 1];141(13):1610–25. Available from: <https://dx.doi.org/10.1182/blood.2021011094>
- 600 35. Bagger FO, Kinalis S, Rapin N. BloodSpot: a database of healthy and malignant
601 haematopoiesis updated with purified and single cell mRNA sequencing profiles.
602 *Nucleic Acids Res* [Internet]. 2019 Jan 8 [cited 2024 Nov 1];47(D1):D881–5. Available
603 from: <https://pubmed.ncbi.nlm.nih.gov/30395307/>
- 604 36. Kuusanmäki H, Leppä AM, Pölönen P, Kontro M, Dufva O, Deb D, et al. Phenotype-
605 based drug screening reveals association between venetoclax response and
606 differentiation stage in acute myeloid leukemia. *Haematologica* [Internet]. 2020 Mar 1
607 [cited 2022 May 13];105(3):708–20. Available from:
608 <https://haematologica.org/article/view/9289>
- 609 37. Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, et al. Monocytic
610 Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute
611 Myeloid Leukemia. *Cancer Discov* [Internet]. 2020 Apr 1 [cited 2024 Nov 1];10(4):536–
612 51. Available from: <https://pubmed.ncbi.nlm.nih.gov/31974170/>
- 613 38. Kuusanmäki H, Kytölä S, Vääntinen I, Ruokoranta T, Ranta A, Huuhtanen J, et al. Ex vivo
614 venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia.
615 *Haematologica* [Internet]. 2023 Jul 1 [cited 2024 Jul 20];108(7):1768–81. Available
616 from: <https://haematologica.org/article/view/haematol.2022.281692>
- 617 39. DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax
618 combined with decitabine or azacitidine in treatment-naive, elderly patients with
619 acute myeloid leukemia. *Blood* [Internet]. 2019 Jan 3 [cited 2024 Jul 20];133(1):7–17.
620 Available from: <https://dx.doi.org/10.1182/blood-2018-08-868752>
- 621 40. Pratz KW, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Döhner H, et al. Long-term
622 follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated
623 acute myeloid leukemia. *Am J Hematol* [Internet]. 2024 Apr 1 [cited 2024 Apr
624 11];99(4). Available from: <https://pubmed.ncbi.nlm.nih.gov/38343151/>
- 625 41. Kytölä S, Vääntinen IM, Ruokoranta T, Partanen A, Holopainen A, Saad J, et al. Ex Vivo
626 Venetoclax Sensitivity Predicts Clinical Response in Acute Myeloid Leukemia in the
627 Prospective VenEx Trial. *Blood* [Internet]. 2024 [cited 2024 Nov 1]; Available from:
628 <http://www.ncbi.nlm.nih.gov/pubmed/39357056>
- 629 42. Stahl M, Menghrajani K, Derkach A, Chan A, Xiao W, Glass J, et al. Clinical and
630 molecular predictors of response and survival following venetoclax therapy in
631 relapsed/refractory AML. *Blood Adv* [Internet]. 2021 Mar 9 [cited 2024 Nov
632 5];5(5):1552. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC7948282/>

- 633 43. Zhang Q, Riley-Gillis B, Han L, Jia Y, Lodi A, Zhang H, et al. Activation of RAS/MAPK
634 pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in
635 acute myeloid leukemia. *Signal Transduction and Targeted Therapy* 2022 7:1 [Internet].
636 2022 Feb 21 [cited 2024 Nov 1];7(1):1–13. Available from:
637 <https://www.nature.com/articles/s41392-021-00870-3>
- 638 44. Moujalled DM, Pomilio G, Ghiurau C, Ivey A, Salmon J, Rijal S, et al. Combining BH3-
639 mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of
640 acute myeloid leukemia. *Leukemia* [Internet]. 2019 Apr 1 [cited 2024 Nov
641 1];33(4):905–17. Available from: <https://pubmed.ncbi.nlm.nih.gov/30214012/>
- 642
- 643

644 **Figure Legends**

645 **Figure 1. Response of AML bone marrow cell populations to MCL-1 inhibitor**
646 **MIK665. A)** An illustration showing the relationship between leukocyte cell viability
647 dose response curves and the drug sensitivity score (DSS). The DSS is a modified
648 area over the cell viability curve, which is directly proportional to the drug sensitivity of
649 a sample. Created with BioRender.com. **B)** Waterfall plot showing the MIK665 DSS
650 values in leukocytes of AML samples (n=42) in decreasing order. DSS cutoffs were
651 used to create sample subgroups based on response to MIK665, such that $DSS \leq 10$
652 was considered resistant (blue), $DSS \geq 20$ was considered sensitive (orange), and 10
653 $< DSS < 20$ was considered intermediate (grey). MIK665 dose-response curves for **C)**
654 leukocytes (relative IC₅₀ values: 5.4 nM, 45 nM, and 134.8 nM for sensitive,
655 intermediate, and resistant samples, respectively), **D)** blast cells (relative IC₅₀ values:
656 2 nM, 44.1 nM and 158.4 nM respectively), **E)** monocytes (IC₅₀ values: 3.8 nM, 14.5
657 nM, and 22.9 nM respectively), and **F)** lymphocytes (IC₅₀ values: 52.6 nM, 97.3 nM,
658 and 84.5 nM respectively). Representative samples with the median DSS from each
659 group are highlighted by thicker lines on the dose-response curves. All cell populations
660 were identified using flow cytometry. MIK665 activity was evaluated in 2 healthy BM
661 samples, resulting in dose-response curves for **G)** leukocytes (DSS: 10 and 12, IC₅₀:
662 192 nM and 36.4 nM) and **H)** lymphocytes (DSS: 10.7 and 14.2, IC₅₀: 204.5 nM and
663 32.1 nM).

664 **Figure 2. Differential gene expression analysis reveals markers of sensitivity**
665 **and resistance to MIK665 in AML. A)** Volcano plot showing genes analyzed in the
666 differential gene expression analysis. Genes to the left of the vertical line represent
667 those upregulated in the resistant group when compared to the sensitive group,

668 whereas those to the right of the line are downregulated genes. Genes above the
669 horizontal line (FDR cutoff at 0.1) are significantly differentially expressed (n=112). The
670 labeled genes are *ABCB1* (enriched in the resistant samples; logFC = -3.54; FDR =
671 0.041), *LILRA2* (logFC = 2.47; FDR = 0.062) and *IL17RA* (logFC = 1.79; FDR = 0.061)
672 (enriched in the sensitive samples), as well as *BCL2*, *MCL1*, and *BCL2L1*. The full list
673 and statistics of the differentially expressed genes are available in Supplementary
674 Table 7. **B)** Scatterplot showing an inverse correlation between *ABCB1* expression
675 and MIK665 DSS in AML samples (n = 42; r = -0.5; p = 0.00071). **C)** Scatterplot
676 showing an inverse correlation between *BCL2L1* and MIK665 DSS in AML samples (n
677 = 42; r = -0.4; p = 0.0079). Correlations were performed using the Spearman method.
678 **D)** Western blot showing the protein expression levels of *ABCB1*, *BCL-2*, *MCL-1*, and
679 *BCL-XL* in a selection of MIK665-sensitive or resistant AML samples. log2FC: log2 fold
680 change; log2CPM: log2 counts per million; FDR: false discovery rate.

681 **Figure 3. DepMap analysis of AML cell line data reveals that high *ABCB1* and**
682 **low *MCL1* expression are associated with *BCL2L1* upregulation and**
683 **dependency on it. **A)** Heatmap showing *ABCB1*, *BCL2*, *MCL1*, and *BCL2L1***
684 **expression (log2CPM) in AML cell lines sorted based on *ABCB1* expression**
685 **(log2CPM). **B)** Heatmap showing dependency (Chronos score) of AML cell lines on**
686 ***BCL2*, *MCL1*, and *BCL2L1*. Cell line order is based on *ABCB1* expression. Boxplots**
687 **representing *BCL2*, *MCL1*, and *BCL2L1* **C)** expression and **D)** dependency in cell lines**
688 **with high (purple) and low (grey) *ABCB1* levels. Log2CPM ≥ 2 was defined as a high**
689 **expression of *ABCB1*, whereas log2CPM < 2 was considered low expression. Each**
690 **dot represents a single cell line. Significance was evaluated using the 2-sample t-test.**
691 log2CPM: log2 counts per million.

692 **Figure 4. ABCB1 inhibition in AML with high ABCB1 expression is predictive of**
693 **MIK665 resistance. A)** Density curves representing the distribution of *ABCB1*
694 expression values across the MIK665 response groups. **B)** Receiver operator
695 characteristic ROC curve of *ABCB1* expression as a predictor of MIK665 resistance.
696 The optimal cutoff value for *ABCB1* was selected using the Youden index and is
697 indicated by the green dot. **C)** Contingency matrix showing the performance statistics
698 of the test when using an *ABCB1* cutoff value of 5.22. Created with BioRender.com.
699 **D)** Dotplot showing the DSS of MIK665 and ABCB1 inhibitor elacridar alone or in
700 combination in AML samples with MIK665 resistance (high *ABCB1*: log2CPM > 6) or
701 MIK665 sensitivity (low *ABCB1*: log2CPM < 6). Grey dots represent the DSS values
702 of the single agents, whereas red dots represent the DSS values of the combination
703 (where one drug is increased along its concentration range while the other is fixed at
704 30 nM). Significance was evaluated using the paired sample t-test. **E)** Western blot
705 showing the protein expression level of ABCB1 in HEL ABCB1 knockout (HEL ABCB1
706 KO) cells, as compared to parental and non-target control (NTC) cells. **F)** Dose-
707 response curves of HEL, HEL ABCB1 knockout and HEL non-target control cells when
708 treated with MIK665 (N=3). Error bars represent the standard deviation. All responses
709 were measured using CellTiter Glo following a 48 h incubation with the drugs.
710 log2CPM: log2 counts per million; AUC: area under the curve.

711 **Figure 5. A combination of MIK665 and BCL-2 inhibitor venetoclax is more**
712 **effective compared to each agent alone in selected AML samples. A)** Results
713 showing the DSS of MIK665 and venetoclax alone or in combination in MIK665-
714 resistant, MIK665-sensitive and venetoclax-resistant AML samples. MIK665-resistant
715 samples were selected as having high *ABCB1* expression (log2CPM > 6) and a
716 MIK665 DSS < 15. MIK665-sensitive samples were selected as having low *ABCB1*

717 expression ($\log_2\text{CPM} < 6$) and a MIK665 DSS > 30 . Venetoclax-resistant samples
718 were selected as having a venetoclax DSS < 10 . Grey dots represent the DSS values
719 of the single agents, whereas orange or purple dots represent the DSS values of the
720 combinations (where one drug is increased along its concentration range while the
721 other is fixed at 30 nM). All responses are measured following a 48 h incubation with
722 the drugs. Significance was evaluated using the paired sample t-test. **B)** Dose
723 response curves of the 3 venetoclax-resistant patient samples as tested in panel A.

724 **Figure 6. A combination of MIK665 and venetoclax is effective in AML cell lines**
725 **with acquired resistance to venetoclax. A)** Dose-response curves of MIK665 and
726 venetoclax alone and in combination in MV4-11 venetoclax-resistant (MV4-11_VenR),
727 Kasumi-1 venetoclax-resistant (Kasumi-1_VenR), MOLM-13 venetoclax-resistant
728 (MOLM-13_VenR) and HL-60 venetoclax-resistant (HL-60_VenR) cell lines, where
729 one drug is increased along its concentration range while the other is fixed at 12.5 nM.
730 Responses are measured by CellTiter-Glo following a 48 h incubation. ZIP synergy
731 scores for the combination in each of the cell line are reported in the table. **B)** Western
732 blot showing the protein expression level of BCL-2, MCL-1, and BCL-XL in parental
733 and VenR cell lines, and the protein quantification normalized to the respective
734 GAPDH levels.


Table 1. Clinical characteristics of the FIMM AML patient cohort.

| | | Total (n=42) |
|---------------------------------|-------------------|---------------------|
| Median age (range), years | | 63 (22-79) |
| Disease Stage | Diagnosis, n (%) | 36 (85.7%) |
| | Relapse, n (%) | 4 (9.5%) |
| | Refractory, n (%) | 2 (4.8%) |
| Median blast percentage (range) | | 70.5 (50-95) |
| FAB | AML M0/1, n (%) | 14 (33.3%) |
| | AML M2, n (%) | 8 (19%) |
| | AML M4, n (%) | 3 (7.1%) |
| | AML M5, n (%) | 5 (11.9%) |
| | NA, n (%) | 12 (28.6%) |

FAB, French-American-British classification; NA, data not available


735

736 **Figure 1. Response of AML bone marrow cell populations to MCL-1 inhibitor**
 737 **MIK665.**




738

739 **Figure 2. Differential gene expression analysis reveals markers of sensitivity**
 740 **and resistance to MIK665 in AML.**




741

742 **Figure 3. DepMap analysis of AML cell line data reveals that high *ABCB1* and**
 743 **low *MCL1* expression are associated with *BCL2L1* upregulation and**
 744 **dependency on it.**




745

746 **Figure 4. ABCB1 inhibition in AML with high ABCB1 expression is predictive of**
 747 **MIK665 resistance.**




748

749 **Figure 5. A combination of MIK665 and BCL-2 inhibitor venetoclax is more**
 750 **effective compared to each agent alone in selected AML samples.**




751

752 **Figure 6. A combination of MIK665 and venetoclax is effective in AML cell lines**
753 **with acquired resistance to venetoclax.**



| Cell line | MV4-11_VenR | Kasumi_VenR | MOLM-13_VenR | HL-60_VenR |
|---------------|-------------|-------------|--------------|------------|
| Synergy score | 48.16 | 24.82 | 47.66 | 15.98 |



754